38 results about "Parathyroid Tetany" patented technology

Disclosed are methods of inhibiting bone resorption and / or promoting bone formation using GLP-2 and related Compounds. The invention has a wide spectrum of important uses including hyperparathyroidism, Paget's disease, hypercalcemia of malignancy, osteolytic lesions produced by bone metastasis, bone loss due to immobilisation or sex hormone deficiency, osteomalacia, hyperostosis and osteopetrosis.

Described herein is a multiplex platform that uses ultrasmall nanoparticles (e.g., C dots and C' dots) to graphically differentiate specific nerves (e.g., sensory nerves vs. motor nerves) for nerve transplants and other surgeries. Also described herein is a multiplex platform that uses ultrasmall nanoparticles (e.g., C dots and C' dots) to graphically differentiate between different types of lymphnodes and / or lymphatic pathways, e.g., to safely and effectively perform vascularized lymph node transplantation in the treatment of lymphedema. Also described herein is a multiplex platform that uses ultrasmall nanoparticles (e.g., C dots and C' dots) to graphically differentiate parathyroid tissue.

The present invention relates to a parathyroid sensing system comprising: a modulator for generating a modulation signal having a predetermined frequency; a lock-in amplifier and a light source whichreceive information on the modulation signal; an excitation filter for transmitting, among light emitting from the light source, only excitation light that excites the parathyroid glands; a probe andan emission filter connected to the probe and selectively transmitting only autofluorescence emitting from the parathyroid glands; a near-infrared sensor for sensing the autofluorescence that has passed through the emission filter, and converting same into an electric signal; and a speaker for generating an alarm through the electric signal. By means of the present invention, the locations of theparathyroid glands may be precisely identified even when lights are turned on in an operating room, and convenience may be provided by alerting a surgeon by means of an alarm when the parathyroid glands are detected. In addition, the locations of the parathyroid glands may be precisely detected, even when the probe is not directly in contact with the parathyroid glands, by using the autofluorescence characteristics of the parathyroid glands.

The present invention relates to the technical field of parathyroid identification, in particular to a method for intraoperative real-time identification of parathyroid glands based on near-infrared autofluorescence, comprising the following steps: imaging suspicious parathyroid glands; obtaining fluorescence spectra of suspicious parathyroid glands and surrounding tissues data; judging whether it is parathyroid in the spectrogram; performing big data analysis; The research on the identification platform combines clinical medicine with optoelectronic technology and artificial intelligence, and will eliminate various subjective and objective interference factors to the greatest extent, and realize real-time, objective, non-invasive, non-contrast agent-free, intelligent and convenient positioning and identification of parathyroid To solve the biggest problem in thyroid surgery, establishing an objective and rapid method for locating and identifying parathyroid glands is of great significance to the development of thyroid surgery.

The invention discloses a glycoside enrichment of Ligustrum lucidum, the preparation method of which comprises the following steps: adding 10-14 times of ethanol with a volume concentration of 50-80% to Ligustrum lucidum, refluxing and extracting for 1-3h, filtering, and Add 8 times the amount of ethanol with a volume concentration of 50-80% to the residue, reflux for extraction for 1-3 hours, filter, combine the two filtrates, recover the solvent, add an appropriate amount of ethyl acetate for extraction, discard the ethyl acetate layer, and add water to the water layer to saturate Extract with n-butanol, combine the water-saturated n-butanol layers, concentrate, and vacuum-dry to obtain the glycoside enrichment of Ligustrum lucidum. The invention also discloses the application of the Ligustrum lucidum glucoside enrichment in the preparation of medicine for treating hypoparathyroidism.

The present invention provides a compound represented by the following general formula (I):or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a compound, and the like. The compound or a pharmaceutically acceptable salt thereof, the pharmaceutical composition containing such a compound, or the like is useful as a medicine or the like for therapy of benign prostatic hyperplasia, cancer, osteoporosis, psoriasis, secondary hyperparathyroidism, chronic glomerulonephritis, lupus nephritis and / or diabetic nephropathy and the like.

The sulfoneamide compounds having the following Formula (1), which can be used as an effective component of a CaSR antagonizing agent useful for prophylaxis and / or treatment of bone disorders including osteoporosis and etc., are provided. The compounds have an excellent activity of promoting PTH secretion. In addition, the compounds are useful as an effective component of a medicament for the prophylaxis and / or treatment of bone disorders such as osteoporosis, bone fracture, hypoparathyroidism and the like.

A compound as represented by formula (I), and optical isomers, solvates, pharmaceutically-acceptable salts, or prodrugs thereof. The present invention has urate transporter 1 (URAT1) inhibitory activity, can be used for treatment of gout and hyperuricemia, and can also be used for treatment of diseases related to abnormal URAT1 activity, such as recurrent gout attacks, gouty arthritis, hypertension, cardiovascular diseases, coronary heart disease, Lesch-Nyhan syndrome, Kearns-Sayre syndrome, kidney diseases, kidney stones, kidney failure, joint inflammations, arthritis, urolithiasis, lead poisoning, hyperparathyroidism, psoriasis, sarcoidosis, or hypoxanthine-guanine phosphoribosyltransferase deficiency. (I)

The present invention relates to the technical field of medical equipment, and it relates to a medical parathyroid tissue syringe, which includes a syringe, a piston, a motor, a blade and a driving mechanism; The inner wall is circumferentially sealed, and the push-pull rod is used to drive the plug body to move axially along the inner wall of the injection barrel; one end of the plug body is provided with a receiving groove; the bottom surface of the receiving groove is provided with a through hole; the motor includes a body and a On the motor shaft, one end of the motor shaft is used to pass through the through hole and connect with the blade; the driving mechanism is used to drive the body to move relative to the plug body, so as to drive the blade to extend or retract into the accommodation groove; and when retracting into the accommodation groove , the blade is in sealing fit with the groove wall of the accommodating groove in the circumferential direction. According to the technical solution of the present invention, when injecting the parathyroid homogenate, the piston can be pushed to the bottom of the injection cylinder, thereby reducing the residue of the parathyroid homogenate in the injection cylinder.